High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)
The article presents the monitoring of a severe course of CINCA/NOMID syndrome diagnosed at late stages. The use of monoclonal antibodies to IL 1 — kanakinumabum — in a patient with chronic neurological cutaneous and articular syndrome was successful: fever, cutaneous and pain syndromes were complet...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2015-11-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/516 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849404738176548864 |
|---|---|
| author | T. V. Sleptsova E. I. Alekseeva K. V. Savostianov A. A. Pushkov T. M. Bazarova S. I. Valieva O. L. Lomakina R. V. Denisova K. B. Isaeva E. G. Chistyakova |
| author_facet | T. V. Sleptsova E. I. Alekseeva K. V. Savostianov A. A. Pushkov T. M. Bazarova S. I. Valieva O. L. Lomakina R. V. Denisova K. B. Isaeva E. G. Chistyakova |
| author_sort | T. V. Sleptsova |
| collection | DOAJ |
| description | The article presents the monitoring of a severe course of CINCA/NOMID syndrome diagnosed at late stages. The use of monoclonal antibodies to IL 1 — kanakinumabum — in a patient with chronic neurological cutaneous and articular syndrome was successful: fever, cutaneous and pain syndromes were completely stopped, joint contractures decreased after one week of therapy. Laboratory parameters of the child’s disease activity (ESR and CRP) became normal after 8 weeks of treatment. Movements in the affected joints recovered completely after 24 weeks; the audiologist noted an improvement in hearing. The above clinical example demonstrates the high efficiency of kanakinumabum for a patient with chronic neurological cutaneous and articular syndrome, and shows the perspective of therapeutic application of IL 1 blocker for patients with CINCA syndrome including advanced stages of the disease. No adverse effects were noted during kanakinumabum therapy. |
| format | Article |
| id | doaj-art-9ae97665029648699710b33facbddec0 |
| institution | Kabale University |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2015-11-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-9ae97665029648699710b33facbddec02025-08-20T03:36:53ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892015-11-0112445656110.15690/pf.v12i4.1428512High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA)T. V. Sleptsova0E. I. Alekseeva1K. V. Savostianov2A. A. Pushkov3T. M. Bazarova4S. I. Valieva5O. L. Lomakina6R. V. Denisova7K. B. Isaeva8E. G. Chistyakova9Scientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian Federation I.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian Federation I.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationThe article presents the monitoring of a severe course of CINCA/NOMID syndrome diagnosed at late stages. The use of monoclonal antibodies to IL 1 — kanakinumabum — in a patient with chronic neurological cutaneous and articular syndrome was successful: fever, cutaneous and pain syndromes were completely stopped, joint contractures decreased after one week of therapy. Laboratory parameters of the child’s disease activity (ESR and CRP) became normal after 8 weeks of treatment. Movements in the affected joints recovered completely after 24 weeks; the audiologist noted an improvement in hearing. The above clinical example demonstrates the high efficiency of kanakinumabum for a patient with chronic neurological cutaneous and articular syndrome, and shows the perspective of therapeutic application of IL 1 blocker for patients with CINCA syndrome including advanced stages of the disease. No adverse effects were noted during kanakinumabum therapy.https://www.pedpharma.ru/jour/article/view/516childrenautoinflammatory syndromescincachronic infantile neurological cutaneous articular syndromekanakinumabunhuman monoclonal antibody to 1 interleukin |
| spellingShingle | T. V. Sleptsova E. I. Alekseeva K. V. Savostianov A. A. Pushkov T. M. Bazarova S. I. Valieva O. L. Lomakina R. V. Denisova K. B. Isaeva E. G. Chistyakova High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA) Педиатрическая фармакология children autoinflammatory syndromes cinca chronic infantile neurological cutaneous articular syndrome kanakinumabun human monoclonal antibody to 1 interleukin |
| title | High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA) |
| title_full | High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA) |
| title_fullStr | High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA) |
| title_full_unstemmed | High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA) |
| title_short | High Efficiency of Kanakinumabum for a Patient with a Late Diagnosed Chronic Infantile Neurological Cutaneous Articular Syndrome (CINCA) |
| title_sort | high efficiency of kanakinumabum for a patient with a late diagnosed chronic infantile neurological cutaneous articular syndrome cinca |
| topic | children autoinflammatory syndromes cinca chronic infantile neurological cutaneous articular syndrome kanakinumabun human monoclonal antibody to 1 interleukin |
| url | https://www.pedpharma.ru/jour/article/view/516 |
| work_keys_str_mv | AT tvsleptsova highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT eialekseeva highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT kvsavostianov highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT aapushkov highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT tmbazarova highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT sivalieva highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT ollomakina highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT rvdenisova highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT kbisaeva highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca AT egchistyakova highefficiencyofkanakinumabumforapatientwithalatediagnosedchronicinfantileneurologicalcutaneousarticularsyndromecinca |